Prothena Corp. (NASDAQ:PRTA) shares shot up 3% during trading on Thursday . The stock traded as high as $52.93 and last traded at $51.46, with a volume of 403,216 shares. The stock had previously closed at $49.98.

PRTA has been the topic of several recent analyst reports. Zacks Investment Research raised Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Friday, May 6th. Credit Suisse Group AG reissued a “buy” rating on shares of Prothena Corp. in a research report on Wednesday, May 4th. Barclays PLC boosted their target price on Prothena Corp. from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, August 4th. Wedbush reissued an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research report on Tuesday, July 5th. Finally, Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corp. in a research report on Friday, June 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $76.60.

The firm’s 50 day moving average is $53.45 and its 200-day moving average is $44.38. The company’s market cap is $1.80 billion.

Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. The firm earned $0.33 million during the quarter, compared to analyst estimates of $0.39 million. The firm’s revenue was up 22.2% compared to the same quarter last year. Equities research analysts forecast that Prothena Corp. will post ($4.25) earnings per share for the current fiscal year.

In related news, insider Arthur W. Homan sold 9,375 shares of Prothena Corp. stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total value of $488,812.50. Following the transaction, the insider now owns 9,375 shares in the company, valued at $488,812.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

A hedge fund recently raised its stake in Prothena Corp. stock. Ameriprise Financial Inc. increased its stake in shares of Prothena Corp. (NASDAQ:PRTA) by 5.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 32,695 shares of the company’s stock after buying an additional 1,832 shares during the period. Ameriprise Financial Inc. owned approximately 0.10% of Prothena Corp. worth $2,227,000 at the end of the most recent reporting period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.